These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34079229)

  • 1. Subcutaneous Interferon Beta Therapy in Multiple Sclerosis Patients - Characterization of Injection Site Reactions and Flu-Like Symptoms in a Daily Practice Setting - Results from the Non-Interventional Study PERFECT.
    Kukowski B; Rehberg-Weber K; Taipale K; Kowalik A; Oschmann P
    Patient Prefer Adherence; 2021; 15():1091-1100. PubMed ID: 34079229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegylated interferon beta-1a (Plegridy) Italian real-world experience: a Delphi analysis of injection-site reaction and flu-like symptom management.
    Cordioli C; Callari G; Fantozzi R; Caruso F; Martucci G; Mascara S; Zipoli V
    Neurol Sci; 2021 Apr; 42(4):1515-1521. PubMed ID: 33439393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global Peginterferon Beta-1a Tolerability Management Best Practices: A Nurse-Focused Delphi Approach.
    White S; Harris C; Allan M; Chieffe C; Eelen P; Röder C; Mouzawak C; Naylor ML
    Neurol Ther; 2021 Jun; 10(1):251-263. PubMed ID: 33761099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks.
    Hendin B; Naismith RT; Wray SE; Huang D; Dong Q; Livingston T; Jones DL; Watson C; Jhaveri M
    Patient Prefer Adherence; 2018; 12():1289-1297. PubMed ID: 30050291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update on Peginterferon beta-1a Management in Multiple Sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists.
    Kolb-Mäurer A; Sunderkötter C; Kukowski B; Meuth SG;
    BMC Neurol; 2019 Jun; 19(1):130. PubMed ID: 31202258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
    Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Reduction of injection site reactions in multiple sclerosis (MS) patients newly started on interferon beta 1b therapy with two different devices].
    Brochet B; Lemaire G; Beddiaf A;
    Rev Neurol (Paris); 2006 Jun; 162(6-7):735-40. PubMed ID: 16840982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient satisfaction with ExtaviPro™ 30G, a new auto-injector for administering interferon β-1b in multiple sclerosis: results from a real-world, observational EXCHANGE study.
    Hoffmann FA; Trenova A; Llaneza MA; Fischer J; Lus G; von Bredow D; Lara N; Lam E; Van Hoef M; Bakshi R
    BMC Neurol; 2017 Aug; 17(1):156. PubMed ID: 28793876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pregnancy outcomes in female multiple sclerosis patients exposed to intramuscular interferon beta-1a or peginterferon beta-1a reported in a German Patient Support Programme - results from the non-interventional post-authorization safety study PRIMA.
    Klehmet J; Begus-Nahrmann Y; Taipale K; Niemczyk G; Rehberg-Weber K
    Ther Adv Neurol Disord; 2023; 16():17562864231214041. PubMed ID: 38107443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The STAR Study: a real-world, international, observational study of the safety and tolerability of, and adherence to, serum-free subcutaneous interferon β-1a in patients with relapsing multiple sclerosis.
    Hupperts R; Ghazi-Visser L; Martins Silva A; Arvanitis M; Kuusisto H; Marhardt K; Vlaikidis N;
    Clin Ther; 2014 Dec; 36(12):1946-1957. PubMed ID: 24811754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of chronotype and timing of interferon injection with severity of IFNβ-induced flu-like syndrome in Multiple sclerosis (MS) patients.
    Maghbooli M; Karami M; Mohammadi V
    J Clin Neurosci; 2024 Oct; 128():110811. PubMed ID: 39197331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in the real-world setting: Interim results from the Plegridy Observational Program.
    Salvetti M; Wray S; Nelles G; Altincatal A; Kumar A; Koster T; Naylor ML;
    Mult Scler Relat Disord; 2022 Jan; 57():103350. PubMed ID: 35158459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can aerobic exercise alleviate flu-like symptoms following interferon beta-1a injections in patients with multiple sclerosis?
    Langeskov-Christensen M; Kjølhede T; Stenager E; Jensen HB; Dalgas U
    J Neurol Sci; 2016 Jun; 365():114-20. PubMed ID: 27206886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients transitioning from non-pegylated to pegylated interferon beta-1a have a low risk of new flu-like symptoms: ALLOW phase 3b trial results.
    Naismith RT; Hendin B; Wray S; Huang D; Gaudenzi F; Dong Q; Sperling B; Mann M; Werneburg B
    Mult Scler J Exp Transl Clin; 2019; 5(1):2055217318822148. PubMed ID: 30729026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A short 2 week dose titration regimen reduces the severity of flu-like symptoms with initial interferon gamma-1b treatment.
    Devane JG; Martin ML; Matson MA
    Curr Med Res Opin; 2014 Jun; 30(6):1179-87. PubMed ID: 24576196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study.
    Camu W; Hadjout K; Latour S; Pöhlau D; Masri S
    Patient Prefer Adherence; 2010 May; 4():127-33. PubMed ID: 20517473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsing-Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study).
    Centonze D; Fantozzi R; Buttari F; Grimaldi LME; Totaro R; Corea F; Marrosu MG; Confalonieri P; Cottone S; Trojano M; Zipoli V
    Front Neurol; 2021; 12():637615. PubMed ID: 33967938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of flu-like syndrome with cetirizine in patients with relapsing-remitting multiple sclerosis during therapy with interferon beta: Results of a randomized, cross-over, placebo-controlled pilot study.
    Landi D; Albanese M; Buttari F; Monteleone F; Boffa L; Rossi S; Motta C; Puma E; Centonze D
    PLoS One; 2017; 12(7):e0165415. PubMed ID: 28686675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study.
    Kleinschnitz C; Niemczyk G; Rehberg-Weber K; Wernsdörfer C
    Int J Mol Sci; 2015 Jul; 16(7):15271-86. PubMed ID: 26154767
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.